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Personal genomic data and the related health data are valuable resources for both 
public-funded research, and for-profit entities in development of new drugs, therapies, 
and diagnostic tests. In order to access to large datasets, pharmaceutical and biotech 
companies have developed partnerships with public and private entities such as direct-to-
consumer genetic testing companies to buy genomic and health related databases collected 
from research participants and customers. Although individuals mainly support data sharing 
for research purposes, the for-profit nature of such data sharing raises some questions 
regarding the rights of the data subjects and fairness in sharing benefits. In response, a new 
generation of sequencing and data sharing startups such as Nebula Genomics, LunaDNA, 
and EncrypGen are emerging which aim for leaving the data control in the hands of each 
individual customer. In particular, such so-called “DNA data marketplaces” allow individuals 
to receive various types of monetary incentives to sequence their genome and share it with 
interested commercial parties. This paper aims to provide an exploratory and critical review 
of the ethical challenges related to establishing such marketplaces for genomic and health 
data sharing. In the view of the growing number of startups developing such marketplaces, 
a thorough analysis of the relevant ethical concerns is timely and needed.
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INTRODUCTION 
Personal genomic data and the related health data are valuable resources for both public-funded 
research, and for-profit entities in development of new drugs, therapies, and diagnostic tests. In order 
to access to large datasets, pharmaceutical, and biotech companies have developed partnerships 
with public and private entities such as direct-to-consumer (DTC) genetic testing companies to buy 
genomic and health related databases collected from research participants and customers.
Most of the customers of DTC companies such as 23andMe opt-in to participate in research 
activities of the service providers and the downstream data sharing by the companies for research 
purposes (Hirschler, 2018). The existing studies with customers have revealed that the underlying 
reasons are mainly out of altruistic motivation to participate in research and help advancement 
of science (Trinidad et al., 2010; Goodman et al., 2017). However, the for-profit nature of sharing 
customers’ data by DTC companies has been perceived objectionable by some customers (Skloot, 
2015). Notably, by giving consent to research, customers should accept that they acquire no rights 
to research, products, or profits that are made and may link to their DNA (Ducharme, 2018). This is 
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viewed as unfair where a clear asymmetry in sharing benefits and 
interests is witnessed.
Moreover, the active participation of the individuals in 
managing sharing and access to their own genomic and health 
data in the framework of the current data sharing models is 
not fully supported. The importance of this matter is recently 
pronounced by the European Data Protection Supervisor in their 
statement: “In principle, individuals should be able to decide 
whether and with whom to share their personal information, 
for what purposes, for how long, and to keep track of them 
and decide to take them back when so wished” (European Data 
Protection Supervisor, 2016).
In response, a new generation of startups are emerging which 
propose, among others, to leave data control in the hands of 
each individual customer (Rosenbaum, 2018). These so-called 
“DNA data marketplaces” propose that people can share their 
data with companies that are interested to have access to their 
data for various research leading to product development 
(Harris, 2018) and receive monetary compensation or incentives 
(Jones, 2018). Although offering direct incentives to individuals 
to engage them in genomic data sharing may seem beneficial, 
this has seen as a sensitive issue drawing a lot of attention in the 
area of research ethics.
In an effort to address the associated concerns with DNA data 
marketplaces, this paper provides an exploratory and critical 
review of the associated ethical challenges related to participation 
of the individuals through analysis of different arguments 
discussed in academic papers and gray literature.
DNA DATA MARKETPLACE: THREE 
EXAMPLEs
In order to illustrate our discussion, we reviewed the information 
provided in the websites of three startups namely Nebula 
Genomics, LunaDNA, and EncrypGen, which enable individuals 
to share their genomic data and related health information and 
receive various monetary incentives. We also consulted the 
information published in other websites in relation to the visions, 
policies, and strategies of these startups.
NEBULA GENOMICs
Nebula Genomics is a startup established by George Church, 
plans to “upend the usual way genomic information is owned,” 
claiming that the current system applied by DTC companies is 
“very paternalistic” (Harris, 2018). Nebula Genomics is aiming 
for establishing a “Nebula marketplace,” where those consenting 
to share their genetic information can earn the cryptocurrency 
called “Nebula tokens” (Buhr, 2018). In Nebula marketplace, 
individuals are meant to acquire and store their own genomic 
sequencing directly from Nebula Genomics (in partnership 
with Veritas) instead of obtaining the service from a personal 
genomics company. The Nebula’s business model anticipates 
that companies and research organizations would be willing to 
pay for the cost of sequencing in exchange to get access to key 
medical information of the individuals involved. To this end, a 
blockchain platform is designed to enable customers to choose 
how and with whom they want their data to be shared, and to be 
compensated for it (Morris, 2018).
Moreover, Nebula aims for assisting pharmaceutical 
companies in recruiting research participants with conditions 
that are interesting for their current studies, by launching an 
anonymized search for such patients. Once contacted by the 
companies, the patients can decide if they will grant access 
to the companies to their genomic and other medical data 
(Harris, 2018).
ENCRYPGEN
EncrypGen is a startup aiming to “bring together genomic data 
sellers and buyers in one platform” (Wilson, 2019) and “looks 
forward to solving the problem of retaining customers’ DNA data 
by DTC companies to be resold to research and development 
companies” (Matthews, 2018). EncrypGen “Gene-Chain” DNA 
Data Marketplace connects individual DNA data owners with 
data buyers and providers of other health related services. The 
Gene-Chain’s aim is to empower users to store and monetize their 
genetic data by sharing it with third parties looking to obtain 
genetic data such as research scientists and pharmaceutical 
companies (Home–EncrypGen | The DNA Data Marketplace–
EncrypGen., 2018).
According to the EncrypGen’s website, the individuals are 
invited to contribute data: “If you have had your DNA tested 
you may upload your raw DNA data file and create a Gene-
Chain profile now. EncrypGen de-identifies the raw DNA data 
file by stripping it away from name, email, and other sensitive 
information. DNA data buyers search Gene-Chain profiles 
suitable for their projects and purchase de-identified genomic 
data with DNA tokens” (Buy DNA Tokens–EncrypGen., 2018). 
In addition, EncrypGen has announced the plans for developing 
partnerships “with testing companies, analytics software 
developers, and various parties, like employee health benefits 
services,” in an attempt to drive more users to the platform and 
monetize data (Levy, 2018).
LUNADNA
LunaDNA is a community-owned platform that is created by 
the Public Benefit Corporation, LunaPBC. LunaDNA offers 
company shares to individuals for contributing their DNA data 
as well as uploading their medical reports and lifestyle health 
activities. Those shares entitle members to a share in the profits 
from medical research and development. Users are supposed 
to get different portions of shares depending on the data they 
provide. For example, if a user donates DNA-targeted genes 
they will receive 10 shares, but if they submit their whole DNA 
genome, they will receive 300 shares (Lovett, 2018).
LunaDNA platform is powered by blockchain technology 
and provides aggregated data to researchers with the consent of 
the involved individuals (Lovett, 2018). In addition, LunaDNA 
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has announced plans for collaboration with pharmaceutical 
companies in the future.
ETHICAL CONCERNs
Participation of the individuals in for-profit data contribution 
startups raises a number of ethical concerns for the rights and 
interests of the individuals and society in general. While some of 
these concerns are related to the impact of incentives strategies 
that such startups utilize on consent and participation in research, 
the other concerns are related to potential privacy concerns that 
may arise from use of emerging technologies such as Blockchain.
Consent-Related Concerns
In the context of DNA data marketplace, the impact of monetary 
incentives on validity of consent should be thoroughly investigated. 
We will discuss the consent-related issues here under two major 
concerns of undue influence and withdrawal of consent.
Undue Influence: Informed consent must be obtained from 
participants under circumstances that minimize the possibility of 
coercion or undue influence. It is important to evaluate whether 
or under what research circumstances financial incentives might 
affect a subject’s judgment, and to what degree the payments 
induce people to participate while having deep objections (Grady, 
2005). For instance, according to the official Institutional Review 
Board guidebook published by the US Office for Human Research 
Protections, “an offer is troublesome if it is so attractive [that it] 
may blind prospective subjects to the risks or impair their ability 
to exercise proper judgment” (U. S. Department of Health and 
Human Services, 1993).
The question here is under what circumstances offering financial 
incentives in exchange for individuals personal and health-related 
data may threat the validity of the consent and compromise the 
participant’s ability to respond reasonably, resulting in undue 
induction the participation. In particular, it is crucial to investigate 
how both patients and healthy participants, with various socio-
economic backgrounds respond to the financial incentives in 
personal data sharing. In traditional research settings, it is expected 
that the research ethics committees assess the risks of undue 
influence that may arise from use of monetary and other incentives 
to recruit research participants. However, in the context of DNA 
data marketplaces it is not clear if such ethics oversight is present to 
assess the ethical underpinnings of offering financial incentives in 
exchange for individuals’ genomic and health-related data.
Other consent-related concerns are based on the nature of 
genetic data. Given the commonly shared genetic information 
among relatives, the involvement of the family members in the 
process of personal genomic data sharing and consent is a matter 
of discussion. Should all family members approve sharing and 
selling of common genetic and health information? And should 
they all benefit from the shares of the same individual account?
Moreover, provision of monetary incentives may have broader 
impact on biomedical research and data sharing, by undermining 
altruistic participation in research. One can argue that public-
funded research that does not offer monetary incentives can be 
negatively impacted as a result of recruitment strategies of DNA 
data marketplaces.
Consent Withdrawal: Research participants should be 
aware that they have the right to freely withdraw their 
consent at any time during the research (Edwards, 2005), and 
voluntary terminate their participation in research (Gabriel 
and Mercado, 2011), without necessarily providing reasons. 
Notably, offering financial incentives to individuals for sharing 
their genomic data could be a barrier to consent withdrawal. 
In particular, the questions arise about whether individuals 
can withdraw their consent after receiving various types of 
financial incentive, such as tokens, shares, or free sequencing 
(Roberts et al., 2017). The procedure of withdrawal could be 
much more complex when individuals have already allowed 
access to their data in return for free sequencing of their 
genome by interested companies.
For instance, the LunaDNA consent policy informs patients 
that: “Your continued consent to LunaDNA’ s use of your Shared 
Data is required for your continued ownership of any shares in 
LunaDNA issued to you in connection with the contribution of 
that Shared Data. If you elect to purge Shared Data for which 
you were issued ownership shares in LunaDNA, LunaDNA will 
redeem (i.e. cancel) those shares, and may also elect to cancel 
certain other shares that may have been issued to you. [ … ] If 
you revoke your consent or delete your account, LunaDNA will 
redeem all shares issued to you.” (LunaDNA, 2018). The other 
two startups however have not provided any information on this 
matter on their website. It is highly recommended that these 
emergent startups establish clear policies regarding consent 
withdrawal and communicate that to the participants.
Blockchain-Based Platforms and Privacy 
Concerns
Sharing personal genomic data raises considerable privacy and 
security concerns, due to unique nature of genomic data that 
contains identifiers which makes the complete de-identification 
of the data hard if not impossible (Wang et al., 2017). In addition, 
genomic data can reveal a wide range of sensitive health and 
non-health related data about the individuals and their family 
members (Genomeweb, 2018). For example, in a study analyzing 
Y-chromosome haplotypes together with combining data from 
genealogical registries, researchers were able to predict the 
surnames of a number of anonymized participants in the dataset 
(Gitschier, 2009).
As it is reported above, some of the startups aim for 
implementing blockchain technology as an approach to better 
protect genomic and health data, while allowing participatory 
control on access to the data. Blockchain is an emerging 
technology of a decentralized, digitized database medium and 
a public ledger of all transactions in the network (Ozercan 
et al., 2018). The key feature of a blockchain is the distributed 
database where the database is present in many copies across 
several computer systems creating a peer-to-peer network 
indicating that there is no longer a centralized body controlling 
access to data (Han et al., 2014; Duan et al., 2016). Arguably, 
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blockchain-based platforms can help to solve the governance 
problems in sharing genomic data by using technical solutions. 
These platforms promise their customers to provide distributed 
data stewardship and control together with provision of effective 
ways for strengthening data access and ownership agreements 
(Shabani, 2019). In terms of the security of the networks, 
although blockchain use is expected to improve data encryption 
(Weintraub, 2018), no technology is infallible and concerns 
about possible hacking and breaching of the blockchain system 
have been noticed by the experts and the platform developers 
(Erickson, 2019).
Nebula Genomics privacy policy includes that they take a 
number of organizational, technical, and physical measures 
to protect the personal information they collect, both during 
transmission and once received. However they note that, “no 
security safeguards are 100% secure and we cannot guarantee the 
security of your information“(Privacy Policy, 2018). Moreover, 
the questions remain about the compatibility of using such 
technologies with applicable data protection regulations in 
different jurisdictions. (Price, 2018).
Finally, the possibility of access by third parties such as for law 
enforcement purposes should be investigated (Weintraub, 2018). 
The Nebula Genomics privacy policy includes the possibility 
of providing such access when required by law or believed to 
be necessary or appropriate to comply with applicable laws 
and lawful requests and legal process (Privacy Policy, 2018). In 
principle, this could be seen at odds with the rationale behind 
blockchain technology, which restricts access to data for those 
who are not part of the network.
Education and Awareness of the Potential 
Risks
Individuals should be encouraged to carefully weigh the benefits 
and risks of getting engaged in a DNA data marketplace. 
Moreover, raising awareness regarding the implications and 
possible consequences of personal genomic data sharing for 
the individuals and their family members is essential (Shabani 
and Borry, 2015). Currently, the potential concerns regarding 
genomic data sharing in the conventional research settings are 
being investigated (Middleton et al., 2018). However, the similar 
studies and educational materials in the context of data sharing 
in DNA data marketplace are missing.
Previously, in the context of Personal Genome Project 
(PGP), following educational videos have been required for 
those who agreed to share their genome publicly. In addition, 
the requirements such as higher level of education has been 
expected from volunteers of PGP (Reuter et al., 2018). Although 
this can be seen as one way to mitigate the concerns regarding 
awareness about the associated risks with such data sharing, 
but it may lead to biasing the sample of participants and work 
against diversity.
Moreover, the associated risks with sharing data through 
DNA data marketplace are not fully known yet. It is expected that 
some of the concerns such as those related to risks for privacy 
emerge only in the future and due to technological advances. The 
participants therefore should be aware of unknown risks.
CONCLUDING REMARKs
The emerging DNA Data marketplaces are promising to 
introduce a fair model of data sharing among individuals and 
the interested parties such as pharmaceutical and biotechnology 
companies. They encourage the individuals to directly take 
part in sharing their data and practice their ownership rights 
regarding their DNA information. However, our analysis showed 
that developing DNA data marketplace raises concerns about 
consent and privacy and may have externalities for public-
funded research that do not offer incentives.
One of the main arguments of developing DNA data 
marketplace is to empower individuals to directly share their 
data and control who can have access to data. In essence, 
empowerment of the individuals by enabling them to actively 
be involved in management of their personal health information 
has recently received an increasing attention. For example, The 
European Data Protection Supervisor published in October 
2016 an opinion on this subject and recognized the potential 
of Personal Information Management Systems (PIMS) as one 
approach for effectively implementing citizens’ rights on their 
personal data at the practical level. PIMS “allow individuals to 
manage their personal data in secure, local or online storage 
systems and share them when and with whom they choose.” 
(European Data Protection Supervisor, 2016).
DNA data marketplace could be seen as an example of such 
approach, aiming for involving individuals in managing how to 
share their health data and with whom. However, in order to truly 
empower patients and individuals, it is crucial to ensure that they 
are adequately informed about the limitations on controlling 
their data once have been shared and accessed by companies and 
interested parties. In addition, the companies should develop fair 
and transparent policies on issues related to consent withdrawal 
in the view of offering tokens, shares, etc. in exchange for data.
Moreover, in discussions related to DNA marketplace, the 
attentions should be paid to the fact that human beings are 
relational beings sharing a lot of genetic details with others, and 
in particular family members. In particular, since genetic data 
carry family connections, the implications of data donation 
and receiving financial incentives for family members should 
be taken into considerations. Currently, the discussions related 
to consent and withdrawal mainly limited to the concerns 
related to individual rights in such data donation, and do 
not sufficiently address the pertinent interests of the family 
members. On practical level, it is also crucial to investigate 
how far family members should/can be involved in the process 
of personal genomic data sharing, including giving informed 
consent. Notably, in the context of genetic data, the applicable 
legal frameworks for personal data protection are predominantly 
limited to recognizing individuals as “data subjects” and do not 
extend to the family members.
In addition, in promoting the notions of self-interest and 
individual empowerment, values such as altruism and solidarity 
in the society should not be undermined (Prainsack, 2018). This 
is particularly may appear concerning to traditional biomedical 
research which relies on altruistic participation of the individuals 
to advance research as a public good. Moreover, offering 
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monetary incentives may be considered as commodifying human 
resources, which has been extensively debated to date, as it may 
lead to undermining individuals’ dignity.
Notably, the success of data collection through such 
marketplaces is hinged on attracting a large number of 
participants; otherwise it would be hard to foresee a significant 
impact on the current way the medical research has been 
performed. It should be noted that currently some of other 
non-profit data sharing platforms such as DNA.Land that 
enables individuals to share their own genome- succeeded 
in collecting more than 150,000 genomes (Check Hayden, 
2015). Therefore, the scalability of DNA data marketplaces 
may be seen as an achievable goal. Moreover, developing DNA 
Data Marketplaces and recruiting individuals directly may be 
considered as a solution to the problem of lack of diversity 
among study groups in biomedical sciences. The future studies 
are needed to survey the participants in such marketplaces and 
examine the level of diversity in terms of nationality, ethnicity, 
gender, and the like.
Finally, the use of the terms such as data ownership, buying 
and selling data, and data control in the context of personal 
genomic and health data should be thoroughly scrutinized, as 
such claims are surrounded by legal and practical uncertainties 
(Blasimme et  al., 2018). One pertinent question is how the 
monetary value of DNA data can be estimated, and how 
this can be ethically and legally enforced (McNulty, 2018). 
EncrypGen declared that the price of access to data would 
be decided by the open market, while LunaDNA proposes 
different pricing for non-profits and corporations. In a recently 
published paper, LunaDNA presented a new model for research 
in which participants are issued US Securities and Exchange 
Commission (SEC)-qualified shares in whatever database 
holds their data. Thereby, “as shareholders, the participants 
would be eligible to receive commercial proceeds generated 
by mining their datasets, effectively transforming them from 
research subjects to partners.”(Curtis and Hereward, 2018; 
Kain et al., 2019).
This calls attention to the necessity of developing adequate 
guidelines, policies (soft-governance tools), and regulations in 
order to ensure both ethical and legal underpinnings of DNA data 
marketplaces as well as transparency and fairness of the procedure. 
That said, the existing national and European regulations regarding 
personal data protection and consumer protection provide general 
framework for some aspects of data collection and processing by 
such data marketplaces, including in relation with consent, data 
portability, and transparency of data processing.
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